High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study

Shahin Gaïni1, Svend Stenvang Pedersen1, Ole Græsbøll Koldkjær2, Court Pedersen1 and Holger Jon Møller3

1Department of Infectious Diseases, Odense University Hospital, Søndre Boulevard 29, DK-5000 Odense C, Denmark
2Department of Clinical Biochemistry, Sønderborg Hospital, Sydvang 1, DK-6400 Sønderborg, Denmark
3Department of Clinical Biochemistry, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark

Corresponding author: Shahin Gaïni, shahin.gaini@ouh.fyns-amt.dk

Received: 29 Dec 2006 Revisions requested: 7 Feb 2007 Revisions received: 16 Feb 2007 Accepted: 8 Mar 2007 Published: 8 Mar 2007

Critical Care 2007, 11:R32 (doi:10.1186/cc5715)

This article is online at: http://ccforum.com/content/11/2/R32

© 2007 Gaïni et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Sepsis is a serious condition with a significant morbidity and mortality. New insight into the immunopathogenesis of sepsis could promote the development of new strategies for diagnosis and therapy. High mobility group box-1 protein (HMGB1) has been known for many years as a nuclear chromosomal protein. Its role as a pro-inflammatory cytokine in sepsis and rheumatoid arthritis has been described recently. The aim of our study was to evaluate HMGB1 as a molecular marker in patients with community-acquired infections.

Methods Patients suspected of having infections/sepsis and admitted to a department of internal medicine were included in the study in a prospective manner. Demographic data, comorbidity, routine biochemistry, microbiological data, infection focus, severity score, and mortality on day 28 were recorded. Plasma and serum were sampled at the time of admission. HMGB1 levels were measured with a commercially available enzyme-linked immunosorbent assay (ELISA). Procalcitonin levels were measured with a TRACE (time-resolved amplified cryptate emission) assay. Lipopolysaccharide-binding protein and interleukin-6 were measured with a chemiluminiscent immunometric assay. Soluble haemoglobin scavenger receptor (sCD163) levels were measured with an in-house ELISA.

Results One hundred and ninety-four patients were included in the study. Levels of HMGB1 are presented as medians and interquartile ranges: healthy controls (0.77 ng/ml, 0.6 to 1.46), non-infected patients (1.54 ng/ml, 0.79 to 2.88), infected patients without systemic inflammatory response syndrome (2.41 ng/ml, 0.63 to 3.44), patients with sepsis (2.24 ng/ml, 1.30 to 3.75), and patients with severe sepsis (2.18 ng/ml, 0.91 to 3.85). In a receiver operator characteristic curve analysis discriminating between non-infected patients and all infected patients, the area under the curve for HMGB1 was 0.59 ($P < 0.0001$). HMGB1 correlated only weakly to levels of white blood cell count, neutrophils, C-reactive protein, interleukin-6, procalcitonin, and lipopolysaccharide-binding protein ($P < 0.001$). HMGB1 did not correlate to sCD163.

Conclusion In a cohort of patients with suspected community-acquired infections and sepsis, HMGB1 levels were statistically significantly higher in patients compared to the healthy controls. There was no statistically significant difference between the infected and the non-infected patients. Levels of HMGB1 correlated only very weakly to other pro-inflammatory markers and did not correlate to the anti-inflammatory marker sCD163.

Introduction

Sepsis is a serious condition with a significant morbidity and mortality [1]. Clinicians treating patients with infections and sepsis are in need of better diagnostic, prognostic, and immunological molecular markers. Better markers for the presence of infection and the degree of inflammation would enable the
Clinician to start relevant therapy as early as possible. Increased insight into the immunopathogenesis of sepsis would offer the potential to generate new treatment options. Sepsis is characterised by an activation of the innate immune system when the immune system is challenged by an invading pathogenic microorganism [2]. This results in the production of pro-inflammatory and anti-inflammatory cytokines [2].

A lot of attention has been given to several pro-inflammatory cytokines involved in sepsis. Cytokines like interleukin (IL)-1, IL-6, and tumour necrosis factor-alpha have been studied in animal models and in clinical sepsis cohorts [3-9]. These cytokines have an important role in initiating the systemic inflammatory response syndrome (SIRS) in the early phases of sepsis. In a laboratory model with cultured macrophages stimulated with endotoxin, high mobility group box-1 protein (HMGB1) was identified as a potential 'late-onset' pro-inflammatory cytokine [10]. It was also observed that mice had increased levels of HMGB1 8 to 32 hours after exposure to endotoxin [10]. Treatment with antibodies against HMGB1 reduced mortality in endotoxin-exposed mice, and administration of HMGB1 increased mortality [10].

HMGB1 levels have been studied in critically ill patients. However, the studies were characterised by few patients in heterogeneous patient populations. Measuring HMGB1 has been quite challenging because no enzyme-linked immunosorbent assay (ELISA) was available until recently. Earlier studies used blotting methods for measuring HMGB1. We have previously shown that C-reactive protein (CRP) and IL-6 were better markers for infection than soluble haemoglobin scavenger receptor (sCD163) in a population of patients prospectively admitted to a department of internal medicine [11]. We have also shown that CRP, lipopolysaccharide-binding protein (LBP), and IL-6 were better diagnostic markers for infection and sepsis than procalcitonin (PCT) in the same cohort of patients [12]. The purpose of the present study was to describe levels of HMGB1 in a non-critically ill population of patients suspected of having sepsis. To perform the study, we used the patient cohort used in two previous studies [11,12].

Materials and methods

Patients

Patients admitted to the department of internal medicine were consecutively included in our study in a five month period in 2003. Odense University Hospital (Odense, Denmark) has 1,200 beds and serves a local population of 185,000 inhabitants. Inclusion criteria were suspected diagnosis of infection 1,200 beds and serves a local population of 185,000 inhabitants [2003. Odense University Hospital (Odense, Denmark) has consecutively included in our study in a five month period in]. Patients admitted to the department of internal medicine were

Materials and methods

Patients

Patients who could not be classified were excluded from the analyses. Patients were divided into the following groups for analyses: non-infected patients, infected patients without SIRS, sepsis patients, and patients with severe sepsis/septic shock. Patients who could not be classified were excluded from the analyses.

Laboratory assays

HMGB1 was measured with a commercially available ELISA (HMGB1 ELISA kit; Shino-Test Corporation, Tokyo, Japan). The measuring range was 0.6 to 93.8 ng/ml. The range could be broadened by dilution of high samples. The coefficients of variation were 5% for samples above 10 ng/ml and 10% for samples from 2 to 5 ng/ml. Recovery of HMGB1 in this ELISA was 92% to 111% [16]. PCT was measured with a TRACE (time-resolved amplified cryptate emission) technology assay (Kryptor PCT®; B·R·A·H·M·S Aktiengesellschaft, Hennigsdorf, Germany). The functional assay sensitivity was 0.06 ng/ml.
Results

Patient characteristics

One hundred and ninety-four patients were included in the study. The patients were divided according to our plan for analyses into the following groups: non-infected patients ($n = 67$), infected patients without SIRS ($n = 32$), patients with sepsis ($n = 47$), and patients with severe sepsis ($n = 27$). Twenty-one patients could not be classified and were excluded from analyses. Only one patient had septic shock. This patient was included in the severe sepsis group. The diagnoses of the non-infected patients were respiratory disease ($n = 22$), cardiovascular disease ($n = 10$), rheumatologic disease ($n = 8$), central nervous system disease ($n = 5$), and various other diseases ($n = 22$). Sixteen patients in the non-infected group were treated with immunosuppressive drugs at the time of admission ($15$ with prednisolone and $1$ with methotrexate). Fifteen of the infected patients (with or without SIRS) were treated with prednisolone at the time of admission. All but one of these patients continued on their immunosuppressive treatment during their hospital stay. The mortality rate among all the infected patients was 3.8%. Thirty-two healthy hospital workers served as a healthy control group for HMGB1 analyses. Baseline characteristics and mortality at day 28 are presented in Table 1. The microbiology and infectious focus are presented in Table 2.

Levels of high mobility group box-1 protein

The levels of HMGB1 were statistically significantly higher among patients compared to the healthy control group ($P < 0.001$) (Table 3). However, there were no statistically significant differences in HMGB1 levels between the following groups: non-infected patients, infected patients without SIRS, patients with sepsis, and patients with severe sepsis (Table 3; Figure 1). When all infected patients (infection without SIRS, sepsis, and severe sepsis) as a group were compared with the non-infected patients, the difference was marginally significant ($P = 0.054$) (Figure 2). Levels of HMGB1 were significantly higher in infected patients (infection without SIRS, sepsis, and severe sepsis) without bacteraemia ($n = 94$) and in patients with bacteraemia ($n = 12$) compared to healthy controls (Figure 3). Levels of HMGB1 were higher among non-infected patients treated with immunosuppressive drugs (median 2.8 ng/ml) compared to non-infected patients not treated with immunosuppressive drugs (median 1.5 ng/ml) ($P < 0.05$). There were no statistically significant differences in HMGB1 levels between infected patients treated with immunosuppressive drugs and infected patients not treated with immunosuppressive drugs. Levels of CRP, PCT, LBP, and IL-6 were statistically significantly higher among all infected patients compared to the non-infected patients (Table 3). Levels of sCD163 were statistically significantly higher only in the group with severe sepsis compared to the non-infected patients (Table 3). Levels of WBC count and neutrophils were statistically significantly higher among patients with sepsis and severe sepsis compared to the non-infected patients (Table 3).

Receiver operating characteristic curve

In an ROC curve analysis to distinguish between the non-infected patients and all infected patients (infection without SIRS, sepsis, and severe sepsis), the markers performed with the following AUCs: HMGB1 0.59 (95% CI 0.5 to 0.68), CRP 0.83 (95% CI 0.77 to 0.89), PCT 0.76 (95% CI 0.69 to 0.84), LBP 0.79 (95% CI 0.72 to 0.86), IL-6 0.82 (95% CI 0.76 to 0.88), sCD163 0.59 (95% CI 0.5 to 0.68), WBC 0.70 (95% CI 0.62 to 0.78), and neutrophils 0.69 (95% CI 0.62 to 0.77). HMGB1 and sCD163 thus performed poorest in this comparative ROC curve analysis (Figure 4).

Correlations

Weak correlations were found between HMGB1 and CRP (Spearman rank correlation coefficient $r = 0.27$, $P < 0.001$), HMGB1 and PCT (Spearman rank correlation coefficient $r = 0.17$, $P < 0.05$), HMGB1 and LBP (Spearman rank correlation coefficient $r = 0.26$, $P < 0.001$), and HMGB1 and IL-6 (Spearman rank correlation coefficient $r = 0.21$, $P < 0.01$).
Correlations of moderate strength were found between HMGB1 and WBC (Spearman rank correlation coefficient \( r = 0.36, P < 0.0001 \)) and HMGB1 and neutrophils (Spearman rank correlation coefficient \( r = 0.42, P < 0.0001 \)). No correlation was found between HMGB1 and sCD163.

**Discussion**

The patients included in our study were representative of patients admitted to a department of internal medicine with the diagnosis of suspected infection. They were elderly patients with a considerable burden of comorbidity. Compared to patients in previous clinical studies focusing on markers of infection and sepsis, our patients were not as ill. This is shown by the relatively low mortality rate, low SOFA scores, and the fact that only one patient had septic shock. Our cohort was therefore dominated by the milder end of the sepsis spectrum. Most previous studies investigating different immunological aspects of sepsis have focused on patients admitted to intensive care units and thus on the more severely ill. We believe that focusing on patients in the milder end of the sepsis spectrum is a strength. In the early phase of infectious/sepsis disease, it is critical to have good diagnostic markers to identify patients in need of effective antibiotic therapy and other supportive care. It is also important to have good prognostic and immunological markers in these patients. If clinicians want to use clinical research results on their patients, the validation of (for instance) sepsis markers will ideally have been performed on a patient sample representative of the clinical reality that faces the clinician. Our study cohort was well characterised, and the sampling and processing of plasma/serum were optimised. We avoided work-up bias in the classification of the infectious status of the patients by blinding the clinicians and laboratory technicians. Drawbacks of this study (as of most other clinical sepsis studies) were heterogeneity among included patients, a heavy burden of comorbidity, and different length of disease prior to hospital admission. Another drawback was the risk of imperfect gold-standard bias in classifying the patients.

HMGB1 is a 215-amino acid protein that has been shown to be highly conserved among different species [19]. It has been known for approximately 30 years as a nuclear chromosomal protein [19,20]. In recent years, there has been a focus on a new role for HMGB1. It has been suggested that HMGB1 has
a role as a pro-inflammatory cytokine [21], and HMGB1 has
been shown to have many organ-specific biological functions,
including inducing fever, anorexia, weight loss, and cytokine
production in the brain; inducing acute lung injury and produc-
tion of pro-inflammatory cytokines/mediators in the lungs; pro-
moting translocation in the gut; inducing arthritis and joint
inflammation; affecting heart rhythm; and having bactericidal
effects [22].

To our knowledge, only three clinical studies with data on
HMGB1 levels in infections and sepsis have been published
[10,23,24]. In one small study with 8 healthy people and 25
patients with sepsis, the highest levels of HMGB1 (median 84
ng/ml) were observed in sepsis patients with a fatal outcome
[10]. Surviving patients had a median level of HMGB1 of 25
ng/ml, and healthy controls had undetectable levels of
HMGB1 [10]. In that study, HMGB1 levels were measured
with an immunoblotting method [10]. In a prospective obser-
vational study, HMGB1 and several other cytokines were
measured over several days in patients who had different
degrees of sepsis and who were admitted to intensive care
units [23]. In that study, HMGB1 was measured with two dif-
ferent immunoblotting methods [23]. Levels of HMGB1
remained elevated in this cohort of critically ill patients up to

Table 2
Microbiological and infection characteristics of the patients

| Variable                        | Infected patients without SIRS (n = 32) | Patients with sepsis (n = 47) | Patients with severe sepsis (n = 27) |
|---------------------------------|----------------------------------------|-----------------------------|-------------------------------------|
| Assessment of infection, number |                                        |                             |                                     |
| Gram-positive bacteria          | 6                                      | 12                          | 10                                  |
| Gram-negative bacteria          | 7                                      | 10                          | 7                                   |
| Other bacteria                  | 0                                      | 2a                          | 0                                   |
| Bacteraemia                     | 1                                      | 4                           | 7                                   |
| Virus                           | 3b                                     | 4c                          | 1d                                  |
| CXR verified pneumoniaa        | 9                                      | 13                          | 7                                   |
| Radiological evidencef         | 0                                      | 1                           | 0                                   |
| Obvious clinical infectiong     | 7                                      | 5                           | 2                                   |
| Focus of infection, number      |                                        |                             |                                     |
| Upper respiratory tract infection| 1                                      | 0                           | 1                                   |
| Lower respiratory tract infection| 12                                     | 25                          | 15                                  |
| Endocarditis                    | 1                                      | 0                           | 1                                   |
| Gastroenteritis                 | 5                                      | 1                           | 0                                   |
| Pyelonephritis                  | 2                                      | 2                           | 1                                   |
| Cystitis                        | 0                                      | 3                           | 3                                   |
| Skin/Soft tissue infection      | 1                                      | 4                           | 3                                   |
| Bone/Joints                     | 2                                      | 1                           | 0                                   |
| Other                           | 8                                      | 11                          | 3                                   |

Mycoplasma pneumoniae (n = 2); Epstein-Barr virus (n = 1), influenza A virus (n = 2); Epstein-Barr virus (n = 2), influenza A virus (n = 2); Puumala virus (n = 1); CXR verified pneumonia with no identified pathogen; infection documented by imaging techniques (other than CXR) with no identified pathogen; clinical infection (for instance, erysipelas, wound infection).

CXR, chest x-ray; SIRS, systemic inflammatory response syndrome.
### Table 3

Levels of HMGB1, PCT, LBP, CRP, IL-6, WBC, and neutrophils in different groups

| Variable       | Healthy controls (n = 32) | Non-infected patients (n = 67) | Infected patients without SIRS (n = 32) | Patients with sepsis (n = 47) | Patients with severe sepsis (n = 27) | \( P \) value<sup>a</sup> |
|----------------|---------------------------|-------------------------------|----------------------------------------|-------------------------------|--------------------------------------|------------------------|
| HMGB1 (ng/ml)  |                           |                               |                                        |                               |                                      | < 0.001                |
| Median         | 0.77                      | 1.54                          | 2.41                                   | 2.24                          | 2.18                                 |                        |
| IQR            | 0.6–1.46                  | 0.79–2.88                     | 0.63–3.44                              | 1.30–3.75                     | 0.91–3.85                            |                        |
| PCT (ng/ml)    |                           |                               |                                        |                               |                                      | < 0.001                |
| Median         | 0.09                      | 0.16                          | 0.2                                    | 1.9                           |                                      |                        |
| IQR            | 0.05–0.13                 | 0.07–0.34                     | 0.08–0.65                              | 0.22–14.6                     |                                      |                        |
| LBP (\( \mu \)g/ml) |                           |                               |                                        |                               |                                      | < 0.001                |
| Median         | 16.3                      | 27.4                          | 33.5                                   | 40.4                          |                                      |                        |
| IQR            | 12.05–25.3                | 18.3–41.2                     | 25.0–43.2                              | 18.0–63.6                     |                                      |                        |
| CRP (mg/l)     |                           |                               |                                        |                               |                                      | < 0.001                |
| Median         | 18                        | 122.0                         | 120.0                                  | 217.0                         |                                      |                        |
| IQR            | 10–42                     | 54.0–215.0                    | 41.0–190.0                             | 78.0–414.0                    |                                      |                        |
| IL-6 (pg/ml)   |                           |                               |                                        |                               |                                      | < 0.001                |
| Median         | 9.8                       | 20.6                          | 72.6                                   | 199.3                         |                                      |                        |
| IQR            | 2.85–21.65                | 9.8–99.4                      | 25.9–274.5                             | 67.5–2,833.0                  |                                      |                        |
| WBC count (10\(^9\)/l) |                           |                               |                                        |                               |                                      | < 0.001                |
| Median         | 8.2                       | 9.5                           | 13.0                                   | 12.2                          |                                      |                        |
| IQR            | 6.7–10.3                  | 7.7–11.9                      | 9.2–17.1                               | 7.0–17.5                      |                                      |                        |
| Neutrophils (10\(^9\)/l) |                           |                               |                                        |                               |                                      | < 0.001                |
| Median         | 6.19                      | 7.1                           | 10.1                                   | 10.3                          |                                      |                        |
| IQR            | 4.73–7.9                  | 5.1–9.7                       | 7.1–14.8                               | 5.5–15.4                      |                                      |                        |
| sCD163 (mg/l)  |                           |                               |                                        |                               |                                      | 0.06                   |
| Median         | 2.99                      | 3.62                          | 3.17                                   | 3.63                          |                                      |                        |
| IQR            | 2.21–4.05                 | 2.44–4.54                     | 2.27–4.64                              | 2.67–5.72                     |                                      |                        |

<sup>a</sup>Kruskal-Wallis test. CRP, C-reactive protein; HMGB1, high mobility group box-1 protein; IL-6, interleukin-6; IQR, interquartile range; LBP, lipopolysaccharide-binding protein; PCT, procalcitonin; sCD163; soluble haemoglobin scavenger receptor; SIRS, systemic inflammatory response syndrome; WBC, white blood cell.
one week after inclusion [23]. Levels of HMGB1, in general, remained elevated for a longer time compared to other cytokines measured in the same cohort [23]. In a recent study, HMGB1 levels were measured with an ELISA in several groups of patients, some of them infected [24]. Mean levels of HMGB1 were as follows: undetectable in healthy controls, 4.54 ng/ml in infected patients, 2.15 ng/ml in patients with malignant disease, 6.47 ng/ml in trauma patients, and 14.05 ng/ml in patients with disseminated intravascular coagulation [24]. High levels were observed in patients with organ failure (mean 8.29 ng/ml) and in fatal cases (mean 16.58 ng/ml) [24]. It is difficult to compare the abovementioned studies; two of them used immunoblotting methods for measuring HMGB1 [10,23] and the other used ELISA [24]. Our study data suggest that HMGB1 levels are much lower in patients in the milder end of the sepsis spectrum. It is possible that the low
levels of HMGB1 in our study could be explained either by the fact that the patients were less ill or by the laboratory method we used to measure HMGB1. The presence of interfering inhibiting factors/autoantibodies to HMGB1 in human serum could affect the results of HMGB1 measurements with ELISA techniques [25]. It is still unknown whether the currently used assays detect biologically active HMGB1. This is an important issue in studies focusing on HMGB1 levels and disease activity. Another explanation could be that we sampled our patients early in their disease course, and this could explain why levels of a 'late-onset' cytokine would be low early after admission. As mentioned earlier, a drawback of the study design was the lack of data on the length of illness before admission. Our data showed no statistically significant difference between the non-infected patients and the infected patients. Our ROC curve analysis confirmed the abovementioned observation showing

Figure 3

Boxplot of HMGB1 levels in healthy controls, infected patients without bacteraemia (P < 0.0001 compared to healthy controls), and patients with bacteraemia (P < 0.05 compared to healthy controls; P = 0.38 compared to infected patients without bacteraemia). HMGB1, high mobility group box-1 protein.

Figure 4

Receiver operating characteristic (ROC) curves comparing the discriminating capabilities of high mobility group box-1 protein (HMGB1), C-reactive protein (CRP), procalcitonin (PCT), lipopolysaccharide-binding protein (LBP), interleukin-6 (IL-6), white blood cell (WBC), neutrophils (neuto), and soluble haemoglobin scavenger receptor (sCD163) between non-infected patients and all infected patients (P < 0.0001).
that HMGB1, in common with sCD163, performed poorly in ROC curve analysis (with an AUC of only 0.59). The trend of lower HMGB1 levels which we observed in the most severely ill patients (severe sepsis and bacteremia) was observed earlier in one of the abovementioned studies [23]. Given the increasing focus on immune paresis as a possible mechanism in severe sepsis and septic shock, this is an interesting observation [26]. If HMGB1 is considered a strong pro-inflammatory cytokine involved in the pro-inflammatory phase of SIRS/sepsis, it could be hypothesised that lower levels could be observed when the patient with severe sepsis/septic shock moves from a pro-inflammatory state to a state with immune paresis. In our study, there was no correlation between an anti-inflammatory marker of sepsis (sCD163) and HMGB1.

Conclusion
This is the first study focusing on HMGB1 levels in a cohort of patients suspected of having community-acquired infections and sepsis and admitted to a department of internal medicine. This cohort was dominated by patients with infections without SIRS, patients with sepsis, and patients with severe sepsis. These sepsis patients were in the mild end of the sepsis spectrum and had low SOFA scores and a low mortality rate. Sixty-seven of the patients were classified as non-infected patients and served as our main control group. Levels of HMGB1 were significantly higher in patients compared to healthy controls. There was no significant difference in levels between the non-infected patients and the infected patients (infection without SIRS, sepsis, and severe sepsis) (P = 0.054). HMGB1 levels correlated only very weakly to other pro-inflammatory markers (CRP, IL-6, PCT, LBP, WBC, and neutrophils). HMGB1 did not correlate only very weakly to other pro-inflammatory markers sCD163. Our data do not suggest that HMGB1 has a role in differentiating between infected and non-infected patients admitted to a department of internal medicine. Further studies are needed to elucidate the role of HMGB1 in the immunopathogenesis of sepsis. Studies focusing on the kinetics of HMGB1 and consecutive measurements of HMGB1 should also be encouraged.

Key messages
- The role of HMGB1 as a nuclear chromosomal protein has been known for many years.
- In recent years, the role of HMGB1 as an inflammatory cytokine has been explored.
- In a cohort of patients suspected of having community-acquired infections and sepsis, levels of HMGB1 were statistically significantly higher in patients compared to the healthy controls.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
SG planned the study, wrote the protocol, collected and analysed data, and wrote the report. OGK was responsible for PCT, IL-6, and LBP analyses. HJM developed the sCD163 in-house ELISA and was responsible for HMGB1 and sCD163 analyses. SSP and CP were involved in planning the study, revising the manuscript, and practical clinical aspects. All authors read and approved the final manuscript.

Acknowledgements
The study was financially supported by the University of Southern Denmark, the M.L. Jørgensen and G. Hansens Foundation, the J. Boserup Foundation, the Odense University Hospital Consultant Foundation, the Foundation for Medical Research in the County of Fyn, the C. Larsen and Judge E. Larsens Foundation, the P.A. Messerschmidt and Wife Foundation, the County of Southern Jutland Research Foundation, the J. Madsen and O. Madsen Foundation, and the Toyota Foundation in Denmark. We thank Joan Clausen and Kirsten Bank Petersen for excellent technical assistance. We also thank study nurses Lene Hergens, Anita Nymark, and Nete Bülow for excellent clinical assistance.

References
1. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999, 340:207-214.
2. Cohen J: The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
3. Haave A, Hal lensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987, 1:355-357.
4. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988, 319:397-400.
5. Waage A, Brandtzæg P, Hal lensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989, 168:333-338.
6. Offner F, Philippe J, Vogelaers D, Colardyn F, Baelie G, Baudrihaye M, Vermeulen A, Leroux-Roels G: Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990, 116:100-105.
7. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lamb thert PH, Schellekens J, Verheoj H, Glauser MP: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 1990, 161:982-987.
8. Munoz C, Misset B, Fitting C, Bleriot JP, Carlet J, Cavaillon JM: Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 1991, 21:2177-2184.
9. Calandra T, Gerani J, Heumann D, Baumgartner JD, Glauser MP: High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991, 91:23-29.
10. Wang H, Bloom C, Zhang M, Vishubhatmak J, Ombrellino M, Che J, Frasier A, Yang H, Ivanova S, Borovkova L, et al.: HMGB-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
11. Gaini S, Koldkjaer OG, Pedersen SS, Pedersen C, Moestrup SK, Möller HJ: Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APIMIS 2006, 114:103-111.
12. Gaini S, Koldkjaer O, Pedersen C, Pedersen S: Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Critical Care 2008, 10:R53.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.

14. Vincent JL, Moreno R, Takala J, Willatts S, De MA, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.

15. Bone RC, Sibbald WJ, Sprung CL: The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992, 101:1481-1483.

16. Yamada S, Yakabe K, Iaishi J, Imaizumi H, Maruyama I: New high mobility group box 1 assay system. Clin Chim Acta 2006, 372:173-178.

17. Moller HJ, Hald K, Moestrup SK: Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 2002, 62:293-299.

18. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.

19. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001, 164:1768-1773.

20. Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999, 19:5237-5248.

21. Andersson U, Tracey KJ: HMGB1 in sepsis. Scand J Infect Dis 2003, 35:577-584.

22. Yang H, Wang H, Czura CJ, Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol 2005, 78:1-8.

23. Sundén-Cullberg J, Norby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573.

24. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I: Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005, 94:975-979.

25. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE: Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007, 81:67-74.

26. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.